Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...

After a parabolic rally in 2018, the cannabis sector came has come back down to earth in 2019. Here's a look at some of the main players in the space, which started perking up again this week. Tilray (NASDAQ: ...

Cronos Group Inc. shares fell 1% Tuesday, after Cowen cut its stock price target to C$17 ($13) from C$21, and said the company has not outlined its path to profitability in Canada and does not have the same scale as rivals Canopy Growth Corp. and Tilray Inc. . Cronos has told investors it expects a long path to profitability as it builds out its international infrastructure with the $1.8 billion investment received from tobacco giant Altria Group . "While U.S. CBD entry via Redwood (Lord Jones) does represent upside tension to our estimates, we do not believe it is enough to warrant a more constructive view on the stock at current multiples, which we think are supported by MO's clear path to control," analyst Vivien Azer wrote in a note. "We continue to like the story, as well as management, and would consider taking a positive position at the right valuation." Azer is sticking with his market perform rating on the stock. Cronos shares have gained 5% in 2019, while the ETFMG Alternative Harvest ETF has fallen 3.3% and the S&P 500 has gained 16%.

Cowen analyst Vivien Azer cut her target because she says recreational pot sales since Canada’s 2018 legalization have been hampered by too few stores, product shortages and the prohibition of popular products like vapes and edibles.